生物样本库市场 - 全球产业规模、份额、趋势、竞争、机会和预测，按类型、样本类型、应用、最终用户、地区和竞争细分，2019-2029F

2023 年全球生物样本库市场估值为 753.4 亿美元，预计在预测期内将强劲成长，到 2029 年复合年增长率为 8.54%。生物样本库作为储存各种类型生物样本（包括血液、组织、细胞和 DNA）以及相关资料（例如病史和生活方式资讯）的储存库。这些储存库在推进生物医学研究方面发挥着至关重要的作用，使科学家能够获得大量多样化的样本来研究疾病、识别生物标记和开发新疗法。推动全球生物样本库市场成长的关键驱动力之一是癌症、心血管疾病和神经系统疾病等慢性疾病的盛行率不断上升。需要来自不同患者群体的经过充分錶征和註释的生物样本对于了解疾病机制、发现新的治疗标靶和评估治疗反应至关重要。此外，生物样本库技术的进步，包括自动化、机器人技术和资料管理系统，正在提高生物样本库营运的效率、可扩展性和品质。精准医疗方法和个人化医疗策略的日益采用正在推动对具有详细分子和临床註释的生物样本的需求。生物样本库为研究人员和临床医生提供全面的样本收集以进行基因型-表型相关性、药物基因组学研究和患者分层工作，在支持精准医疗计划方面发挥关键作用。因此，全球生物样本库市场可望持续扩张，为生物样本库组织、医疗机构和生命科学公司提供重要机会，为生物医学研究和治疗创新做出贡献。

主要市场驱动因素

高品质生物样本的需求不断增长

生物样本库技术的进步

慢性病盛行率不断上升

主要市场挑战

样品品质和完整性

数据管理和集成

主要市场趋势

疾病特异性生物库的扩展

转向虚拟生物银行

细分市场洞察

类型洞察

应用洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球生物样本库市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 按类型（面向疾病的生物库、基于人群的生物库、组织生物库、其他）
  • 依样本类型（血液製品、生物液体、核酸、细胞系、其他）
  • 按应用（治疗、药物发现、临床诊断、临床研究）
  • 按最终用户（学术研究机构、製药生物技术公司、医院诊所等）
  • 按地区
  • 按公司划分 (2023)
• 市场地图
  • 按类型
  • 依样品类型
  • 按申请
  • 按最终用户
  • 按地区

第 6 章：亚太地区生物样本库市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 按类型
  • 依样品类型
  • 按申请
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 7 章：欧洲生物样本库市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 按类型
  • 依样品类型
  • 按申请
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 英国
  • 义大利
  • 德国
  • 西班牙

第 8 章：北美生物样本库市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 按类型
  • 依样品类型
  • 按申请
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 9 章：南美洲生物样本库市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 按类型
  • 依样品类型
  • 按申请
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲生物样本库市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 按类型
  • 依样品类型
  • 按申请
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势发展

• 最近的发展
• 产品发布
• 併购

第 13 章：全球生物样本库市场：SWOT 分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第 15 章：公司简介

• 丹纳赫公司
  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（如果是上市公司）
  • 最近的发展
  • SWOT分析
• 默克公司
• 贝克顿迪金森公司
• 阿万托公司
• 赛默飞世尔科技公司
• 帝肯贸易公司
• 凯杰公司
• 汉密尔顿公司
• ProMedDx 有限公司
• ISENET 生物银行有限公司

第 16 章：策略建议

第 17 章：关于我们免责声明

Global Biobanks Market was valued at USD 75.34 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 8.54% through 2029. The Global Biobanks Market is experiencing substantial growth driven by increasing demand for high-quality biological samples for research, clinical trials, and personalized medicine initiatives. Biobanks serve as repositories for storing various types of biological specimens, including blood, tissues, cells, and DNA, along with associated data such as medical histories and lifestyle information. These repositories play a crucial role in advancing biomedical research, enabling scientists to access large and diverse collections of samples for studying diseases, identifying biomarkers, and developing new therapeutics. One of the key drivers fueling the growth of the Global Biobanks Market is the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. The need for well-characterized and annotated biospecimens from diverse patient populations is essential for understanding disease mechanisms, discovering novel therapeutic targets, and evaluating treatment responses. Additionally, advancements in biobanking technologies, including automation, robotics, and data management systems, are enhancing the efficiency, scalability, and quality of biobanking operations. The increasing adoption of precision medicine approaches and personalized healthcare strategies is driving the demand for biospecimens with detailed molecular and clinical annotations. Biobanks play a pivotal role in supporting precision medicine initiatives by providing researchers and clinicians with access to comprehensive collections of samples for genotype-phenotype correlations, pharmacogenomics studies, and patient stratification efforts. As a result, the Global Biobanks Market is poised for continued expansion, offering significant opportunities for biobanking organizations, healthcare institutions, and life sciences companies to contribute to biomedical research and therapeutic innovation.

Key Market Drivers

Rising Demand for High-Quality Biological Samples

The Global Biobanks Market is experiencing a surge in demand for high-quality biological samples driven by the increasing need for reliable biospecimens in biomedical research, drug development, and clinical applications. High-quality biological samples are essential for studying disease mechanisms, identifying biomarkers, and developing novel therapeutics, making biobanks indispensable resources in the life sciences industry. One of the primary factors fueling the rising demand for high-quality biological samples is the growing emphasis on precision medicine and personalized healthcare. Precision medicine approaches aim to tailor medical treatments to individual patients based on their genetic makeup, lifestyle factors, and environmental influences. As such, there is a heightened need for biospecimens with detailed molecular and clinical annotations to support genotype-phenotype correlations, pharmacogenomics studies, and patient stratification efforts. The increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions is driving the demand for biospecimens for disease research and therapeutic development. Biobanks provide researchers and clinicians with access to diverse collections of well-characterized biological samples from various patient populations, enabling the investigation of disease etiology, progression, and treatment responses. Advancements in biobanking technologies have also contributed to the rising demand for high-quality biological samples. Automation, robotics, and data management systems have improved the efficiency, scalability, and reliability of biobanking operations, enabling biobanks to store, process, and manage large volumes of biospecimens and associated data with greater precision and consistency. The increasing adoption of biobanking practices in translational research, clinical trials, and population health studies further drives the demand for high-quality biological samples. Biobanks play a crucial role in facilitating collaborations between academia, industry, and healthcare sectors, fostering innovation and accelerating the development of new diagnostics, therapeutics, and personalized medicine approaches. The rising demand for high-quality biological samples underscores the critical role of biobanks in advancing biomedical research and improving patient care, driving growth and expansion in the Global Biobanks Market.

Advancements in Biobanking Technologies

Advancements in biobanking technologies have revolutionized the landscape of the Global Biobanks Market, enhancing the efficiency, scalability, and reliability of biological sample storage, management, and analysis. These technological innovations have propelled the field of biobanking forward, enabling biobanks to meet the growing demands of researchers, clinicians, and pharmaceutical companies for high-quality biospecimens. One significant advancement in biobanking technology is the implementation of automation and robotics systems. Automated sample handling and processing equipment streamline biobanking workflows, reducing human error, increasing throughput, and improving sample integrity. Robotics platforms enable precise and consistent sample retrieval, aliquoting, and storage, ensuring sample quality and minimizing contamination risks. The advancements in data management systems have revolutionized biobank operations by facilitating efficient sample tracking, inventory management, and data integration. Electronic laboratory information management systems (LIMS) and biobanking software solutions enable real-time monitoring of sample locations, conditions, and associated metadata, ensuring traceability and compliance with regulatory requirements. The innovations in sample preservation and storage technologies have expanded the capabilities of biobanks to store diverse types of biological specimens under optimal conditions. State-of-the-art cryopreservation methods, such as automated liquid nitrogen storage systems and vapor-phase nitrogen freezers, ensure long-term sample viability while minimizing degradation and sample loss. The emerging technologies such as blockchain and artificial intelligence (AI) hold promise for enhancing data security, privacy, and analysis capabilities within the biobanking sector. Blockchain-based systems enable secure and transparent management of sample-related transactions and data sharing, while AI algorithms offer powerful tools for data analysis, pattern recognition, and predictive modeling in biobanking research. The advancements in biobanking technologies are driving innovation, efficiency, and collaboration within the Global Biobanks Market, empowering researchers and clinicians to accelerate biomedical research, drug discovery, and personalized medicine initiatives. Continued investments in technology development and infrastructure are expected to further propel the growth and evolution of the biobanking industry in the years to come.

Growing Prevalence of Chronic Diseases

The growing prevalence of chronic diseases is a significant driver shaping the trajectory of the Global Biobanks Market. Chronic diseases, including cancer, cardiovascular disorders, diabetes, and neurological conditions, pose significant public health challenges worldwide, contributing to a substantial burden of morbidity and mortality. As the incidence of chronic diseases continues to rise globally, there is an increasing need for high-quality biological samples to support research efforts aimed at understanding disease mechanisms, identifying biomarkers, and developing effective treatments. Biobanks play a crucial role in addressing the growing prevalence of chronic diseases by providing researchers, clinicians, and pharmaceutical companies with access to diverse collections of well-characterized biological specimens. These biospecimens, which include blood, tissues, cells, and DNA samples, are essential for studying disease etiology, progression, and treatment responses. For instance, biobanks enable researchers to investigate genetic and environmental factors contributing to the development of chronic diseases, facilitating the discovery of novel biomarkers for early detection, prognosis, and personalized treatment approaches. Additionally, biobanks support translational research efforts by providing access to clinical samples from large and diverse patient populations, enabling the validation of new diagnostic tools and therapeutic interventions. The biobanks play a critical role in supporting longitudinal studies and population health research initiatives aimed at identifying risk factors, trends, and disparities in chronic disease prevalence and outcomes. By collecting and analyzing longitudinal data and biospecimens from individuals over time, biobanks contribute valuable insights into disease trajectories, treatment responses, and long-term health outcomes. The growing prevalence of chronic diseases underscores the importance of biobanking in advancing biomedical research, improving clinical care, and addressing global health challenges. Continued investments in biobank infrastructure, technology, and collaboration are essential for meeting the increasing demand for high-quality biological samples and driving innovation in chronic disease prevention, diagnosis, and treatment.

Key Market Challenges

Sample Quality and Integrity

Sample quality and integrity are paramount in the Global Biobanks Market to ensure the reliability and reproducibility of research findings and clinical applications. Challenges related to sample quality and integrity include the risk of degradation over time, variability in sample collection and processing methods, and the potential for contamination. Maintaining sample quality starts with rigorous adherence to standardized protocols for sample collection, processing, and storage. Proper handling techniques, such as ensuring appropriate temperature control and using preservatives, are essential to minimize degradation and maintain sample integrity. The robust quality control measures, including regular sample monitoring, testing for contamination, and validation of sample identity, are crucial for ensuring the accuracy and reliability of stored samples. Biobanks invest in state-of-the-art infrastructure and employ advanced technologies to safeguard sample quality and integrity. These include automated sample handling systems, stringent quality assurance protocols, and comprehensive data management systems to track sample provenance and ensure compliance with regulatory requirements. By prioritizing sample quality and integrity, biobanks can enhance the utility and value of their repositories, enabling researchers, clinicians, and pharmaceutical companies to access high-quality biological specimens for a wide range of biomedical research and clinical applications.

Data Management and Integration

In the Global Biobanks Market, effective data management and integration are critical for maximizing the utility of biological samples and associated data for research and clinical applications. Biobanks collect and store vast amounts of data, including clinical, genetic, and molecular information, alongside biological specimens. Managing and integrating this diverse array of data presents several challenges. One challenge is the need to establish robust data management systems capable of handling large volumes of data while ensuring security, privacy, and compliance with regulatory requirements. Biobanks must implement advanced data storage, retrieval, and sharing mechanisms to facilitate efficient data management across different research projects and collaborations. The integrating data from disparate sources poses challenges related to data harmonization, standardization, and interoperability. Biobanks must adopt standardized data formats, ontologies, and metadata standards to facilitate data integration and enable cross-study comparisons. Advancements in technologies such as cloud computing, artificial intelligence, and blockchain offer opportunities to enhance data management and integration capabilities within the biobanking sector. These technologies enable real-time data processing, analysis, and sharing, improving data accessibility, collaboration, and knowledge discovery. By addressing challenges related to data management and integration, biobanks can unlock the full potential of their repositories, enabling researchers, clinicians, and policymakers to access comprehensive datasets for advancing biomedical research, drug discovery, and personalized medicine initiatives. Collaborative efforts to establish best practices, standards, and infrastructure for data management and integration are essential for driving innovation and accelerating progress in the field of biobanking.

Key Market Trends

Expansion of Disease-specific Biobanks

The expansion of disease-specific biobanks is a significant trend shaping the Global Biobanks Market. These biobanks focus on collecting, storing, and managing biospecimens from patients with specific diseases or conditions, catering to the specialized needs of researchers and clinicians in targeted research areas. One key driver behind the expansion of disease-specific biobanks is the growing recognition of the heterogeneity and complexity of diseases. By focusing on specific diseases or conditions, these biobanks enable researchers to access well-characterized samples that are relevant to their research interests, facilitating more targeted investigations into disease mechanisms, biomarker discovery, and therapeutic development. The disease-specific biobanks play a crucial role in advancing precision medicine initiatives. By collecting biospecimens from patients with specific diseases, these biobanks contribute to the development of personalized treatment strategies tailored to individual patients' genetic makeup, lifestyle factors, and disease characteristics. For example, cancer biobanks collect tumor samples from patients with different types and stages of cancer, enabling researchers to identify biomarkers associated with treatment response and prognosis and develop targeted therapies. Disease-specific biobanks foster collaboration among researchers, clinicians, and patient advocacy groups focused on specific diseases. By providing a centralized repository of biospecimens and associated clinical data, these biobanks facilitate knowledge sharing, data analysis, and resource pooling, accelerating research progress and improving patient outcomes. The expansion of disease-specific biobanks reflects a growing emphasis on precision medicine, personalized healthcare, and collaborative research initiatives within the Global Biobanks Market. Continued investment in disease-specific biobanking infrastructure, technology, and collaboration is essential for addressing the complex challenges associated with various diseases and driving innovation in biomedical research and clinical care...

Shift towards Virtual Biobanking

The Global Biobanks Market is witnessing a notable shift towards virtual biobanking, a trend characterized by the sharing of data and biospecimens across multiple biobanks and research institutions. Virtual biobanking offers several advantages over traditional, centralized biobanking models, including increased collaboration, data sharing, and resource optimization. One of the key drivers behind the shift towards virtual biobanking is the growing recognition of the need for large, diverse datasets to support biomedical research and personalized medicine initiatives. By enabling researchers to access a wider range of samples and data from multiple biobanks, virtual biobanking facilitates more comprehensive and robust analyses, leading to a deeper understanding of disease mechanisms, biomarker discovery, and therapeutic development. The virtual biobanking promotes collaboration and knowledge exchange among researchers, clinicians, and institutions worldwide. By sharing data and resources, researchers can leverage each other's expertise, infrastructure, and sample collections, accelerating research progress and maximizing the impact of limited resources. Virtual biobanking enables biobanks to overcome logistical and ethical challenges associated with sample sharing. By implementing standardized protocols, data sharing agreements, and quality control measures, virtual biobanks ensure the ethical and responsible use of biospecimens and associated data while protecting patient privacy and confidentiality. Virtual biobanking facilitates data integration and analysis across different research projects and institutions, enabling researchers to perform cross-study comparisons, meta-analyses, and validation studies more efficiently. This approach enhances the reproducibility and generalizability of research findings and promotes transparency and accountability within the scientific community. The shift towards virtual biobanking reflects a growing emphasis on collaboration, data sharing, and innovation in the Global Biobanks Market. Continued investment in virtual biobanking infrastructure, technology, and governance frameworks is essential for realizing the full potential of this transformative approach in advancing biomedical research and improving patient care.

Segmental Insights

Type Insights

Based ontype,disease-oriented biobanks segment dominated the Global Biobanks Market in 2023.This is ascribed to the specialized focus on collecting biospecimens from patients with specific diseases or conditions. This targeted approach facilitates in-depth research into disease mechanisms, biomarker discovery, and therapeutic development, catering to the diverse needs of researchers and clinicians. Disease-oriented biobanks enable precision medicine initiatives by providing well-characterized samples relevant to individual diseases, driving advancements in personalized healthcare. Additionally, the collaborative nature of disease-oriented biobanks fosters partnerships among researchers, clinicians, and patient advocacy groups, further enhancing their prominence in the biobanking landscape.

Application Insights

Based on application, drug discovery segment dominated the Global Biobanks Market in 2023. This is ascribed due to due to the increasing demand for high-quality biological samples to support drug development efforts. Biobanks provide researchers with access to diverse collections of well-characterized biospecimens, enabling the identification of novel drug targets, evaluation of drug efficacy and safety, and optimization of therapeutic interventions. Additionally, advancements in biobanking technologies and collaborations between biobanks and pharmaceutical companies further bolster the role of biobanks in drug discovery. The potential to accelerate the drug development process and bring new treatments to market drives significant investment and focus on the Drug Discovery segment within the Global Biobanks Market.

Regional Insights

North America leads the Global Biobanks Market, due to several factors. The region boasts advanced healthcare infrastructure and significant investments in biomedical research, fostering the establishment of numerous high-quality biobanks. North America is home to many leading pharmaceutical and biotechnology companies, driving demand for biological samples for drug discovery and development. The supportive regulatory frameworks and strong academic and research institutions contribute to the region's leadership in biobanking. The presence of a highly skilled workforce and a culture of innovation further strengthens North America's position in the Global Biobanks Market. Overall, the combination of robust infrastructure, industry expertise, regulatory support, and research capabilities makes North America a dominant player in the biobanking landscape.

Key Market Players

Danaher Corporation

Merck KgaA

Becton, Dickinson, and Company

Avantor, Inc.

Thermo Fisher Scientific, Inc

Tecan Trading AG

QIAGEN N.V.

Hamilton Company

ProMedDx, LLC

ISENET Biobanking S.r.l

Report Scope:

In this report, the Global Biobanks Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Biobanks Market,By Type:

• Disease Oriented Biobanks
• Population Based Biobanks
• Tissue Biobanks
• Others

Global Biobanks Market,By Sample Type:

• Blood Products
• Biological Fluids
• Nucleic Acid
• Cell Lines
• Others

Global Biobanks Market,ByApplication:

• Therapeutics
• Drug Discovery
• Clinical Diagnostics
• Clinical Research

Global Biobanks Market,ByEnd User:

• Academic Research Institutes
• Pharmaceutical Biotechnology Companies
• Hospitals Clinics
• Others

Global Biobanks Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biobanks Market.

Available Customizations:

Global Biobanks Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global Biobanks Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Type (Disease Oriented Biobanks, Population Based Biobanks, Tissue Biobanks, Others)
  • 5.2.2.By Sample Type (Blood Products, Biological Fluids, Nucleic Acid, Cell Lines, Others)
  • 5.2.3.By Application (Therapeutics, Drug Discovery, Clinical Diagnostics, Clinical Research)
  • 5.2.4.By End User (Academic Research Institutes, Pharmaceutical Biotechnology Companies, Hospitals Clinics, Others)
  • 5.2.5.By Region
  • 5.2.6.By Company (2023)
• 5.3.Market Map
  • 5.3.1.By Type
  • 5.3.2.By Sample Type
  • 5.3.3.By Application
  • 5.3.4.By End User
  • 5.3.5.By Region

6.Asia Pacific Biobanks Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Type
  • 6.2.2.By Sample Type
  • 6.2.3.By Application
  • 6.2.4.By End User
  • 6.2.5.By Country
• 6.3.Asia Pacific: Country Analysis
  • 6.3.1.China Biobanks Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Type
      • 6.3.1.2.2.By Sample Type
      • 6.3.1.2.3.By Application
      • 6.3.1.2.4.By End User
  • 6.3.2.India Biobanks Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Type
      • 6.3.2.2.2.By Sample Type
      • 6.3.2.2.3.By Application
      • 6.3.2.2.4.By End User
  • 6.3.3.Japan Biobanks Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Type
      • 6.3.3.2.2.By Sample Type
      • 6.3.3.2.3.By Application
      • 6.3.3.2.4.By End User
  • 6.3.4.South Korea Biobanks Market Outlook
    • 6.3.4.1.Market Size Forecast
      • 6.3.4.1.1.By Value
    • 6.3.4.2.Market Share Forecast
      • 6.3.4.2.1.By Type
      • 6.3.4.2.2.By Sample Type
      • 6.3.4.2.3.By Application
      • 6.3.4.2.4.By End User
  • 6.3.5.Australia Biobanks Market Outlook
    • 6.3.5.1.Market Size Forecast
      • 6.3.5.1.1.By Value
    • 6.3.5.2.Market Share Forecast
      • 6.3.5.2.1.By Type
      • 6.3.5.2.2.By Sample Type
      • 6.3.5.2.3.By Application
      • 6.3.5.2.4.By End User

7.Europe Biobanks Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Type
  • 7.2.2.By Sample Type
  • 7.2.3.By Application
  • 7.2.4.By End User
  • 7.2.5.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.France Biobanks Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Type
      • 7.3.1.2.2.By Sample Type
      • 7.3.1.2.3.By Application
      • 7.3.1.2.4.By End User
  • 7.3.2.United Kingdom Biobanks Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Type
      • 7.3.2.2.2.By Sample Type
      • 7.3.2.2.3.By Application
      • 7.3.2.2.4.By End User
  • 7.3.3.Italy Biobanks Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Type
      • 7.3.3.2.2.By Sample Type
      • 7.3.3.2.3.By Application
      • 7.3.3.2.4.By End User
  • 7.3.4.Germany Biobanks Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Type
      • 7.3.4.2.2.By Sample Type
      • 7.3.4.2.3.By Application
      • 7.3.4.2.4.By End User
  • 7.3.5.Spain Biobanks Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Type
      • 7.3.5.2.2.By Sample Type
      • 7.3.5.2.3.By Application
      • 7.3.5.2.4.By End User

8.North America Biobanks Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Type
  • 8.2.2.By Sample Type
  • 8.2.3.By Application
  • 8.2.4.By End User
  • 8.2.5.By Country
• 8.3.North America: Country Analysis
  • 8.3.1.United States Biobanks Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Type
      • 8.3.1.2.2.By Sample Type
      • 8.3.1.2.3.By Application
      • 8.3.1.2.4.By End User
  • 8.3.2.Canada Biobanks Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Type
      • 8.3.2.2.2.By Sample Type
      • 8.3.2.2.3.By Application
      • 8.3.2.2.4.By End User
  • 8.3.3.Mexico Biobanks Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Type
      • 8.3.3.2.2.By Sample Type
      • 8.3.3.2.3.By Application
      • 8.3.3.2.4.By End User

9.South America Biobanks Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Type
  • 9.2.2.By Sample Type
  • 9.2.3.By Application
  • 9.2.4.By End User
  • 9.2.5.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Biobanks Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Type
      • 9.3.1.2.2.By Sample Type
      • 9.3.1.2.3.By Application
      • 9.3.1.2.4.By End User
  • 9.3.2.Argentina Biobanks Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Type
      • 9.3.2.2.2.By Sample Type
      • 9.3.2.2.3.By Application
      • 9.3.2.2.4.By End User
  • 9.3.3.Colombia Biobanks Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Type
      • 9.3.3.2.2.By Sample Type
      • 9.3.3.2.3.By Application
      • 9.3.3.2.4.By End User

10.Middle East and Africa Biobanks Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Type
  • 10.2.2.By Sample Type
  • 10.2.3.By Application
  • 10.2.4.By End User
  • 10.2.5.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Biobanks Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Type
      • 10.3.1.2.2.By Sample Type
      • 10.3.1.2.3.By Application
      • 10.3.1.2.4.By End User
  • 10.3.2.Saudi Arabia Biobanks Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Type
      • 10.3.2.2.2.By Sample Type
      • 10.3.2.2.3.By Application
      • 10.3.2.2.4.By End User
  • 10.3.3.UAE Biobanks Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Type
      • 10.3.3.2.2.By Sample Type
      • 10.3.3.2.3.By Application
      • 10.3.3.2.4.By End User
  • 10.3.4.Egypt Biobanks Market Outlook
    • 10.3.4.1.Market Size Forecast
      • 10.3.4.1.1.By Value
    • 10.3.4.2.Market Share Forecast
      • 10.3.4.2.1.By Type
      • 10.3.4.2.2.By Sample Type
      • 10.3.4.2.3.By Application
      • 10.3.4.2.4.By End User

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Recent Developments
• 12.2.Product Launches
• 12.3.Mergers Acquisitions

13.Global Biobanks Market: SWOT Analysis

14.Porter's Five Forces Analysis

• 14.1.Competition in the Industry
• 14.2.Potential of New Entrants
• 14.3.Power of Suppliers
• 14.4.Power of Customers
• 14.5.Threat of Substitute Product

15.Company Profile

• 15.1.Danaher Corporation
  • 15.1.1.Business Overview
  • 15.1.2.Company Snapshot
  • 15.1.3.Products Services
  • 15.1.4.Financials (In case of listed)
  • 15.1.5.Recent Developments
  • 15.1.6.SWOT Analysis
• 15.2.Merck KGaA
• 15.3.Becton, Dickinson, and Company
• 15.4.Avantor, Inc.
• 15.5.Thermo Fisher Scientific, Inc
• 15.6.Tecan Trading AG
• 15.7.QIAGEN N.V.
• 15.8.Hamilton Company
• 15.9.ProMedDx, LLC
• 15.10.ISENET Biobanking S.r.l

16.Strategic Recommendations

17. About Us Disclaimer